Accurate Response Assessments Vital to Cancer Treatments

When it comes to cancer treatment, part of the challenge is in gauging efficacy. Researchers are investigating new ways to evaluate responses to cancer treatment that could provide valuable information on finding the best methods to improve patient outcomes. In a study published in Future Oncology, researchers compared real-world charted data to radiographic measurements of lesions using Response Evaluation Criteria in Solid Tumors (RECIST). Data was collected from 59 metastatic Merkel cell cancer patients, and revealed that treatment response rates using RECIST assessments were lower. Subjective evaluations of tumor responses through traditional methods may overestimate benefits of treatment and limit the potential of further research. Also, target lesion measurement tools like RECIST may provide more accurate response reporting, the study concludes.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More